Table 4. Multivariable regression model results for VA changes between baseline, 1st year and 2nd years excluding patients with ND lesion type (wet vs dry set, 1stCA, 2ndCA).

	VA change after Year 1				VA change after Year 2
Variable	Estimate	SE	t value	Pr (>|t|)	Estimate	SE	t value	Pr (>|t|)
Intercept	36.6528	11.3307	3.2348	0.0014	45.6233	13.5096	3.3771	0.0009
Age (1 year increase)	−0.3347	0.1244	−2.6899	0.0077	−0.3982	0.1583	−2.5152	0.0128
Gender: male vs female	2.2303	2.1679	1.0288	0.3047	0.1000	2.5592	0.0391	0.9689
Baseline VA (ETDRS)	0.5946	0.0538	11.0539	0.0000	0.5724	0.0596	9.6021	0.0000
Time to treatment (1 day increase)	0.0003	0.0118	0.0288	0.9771	0.0188	0.0377	0.4970	0.6199
Lesion type: Mixed vs classic	−3.1347	3.5904	−0.8731	0.3836	0.9366	4.4350	0.2112	0.8330
Lesion type: occult vs classic	0.1421	2.5443	0.0558	0.9555	5.2651	3.0005	1.7547	0.0811
Lesion type: PCV vs classic	1.3318	5.6620	0.2352	0.8143	11.8228	6.0292	1.9609	0.0516
Lesion type: RAP vs classic	0.5021	3.7943	0.1323	0.8948	−5.3562	4.2839	−1.2503	0.2129
Number of injections in the first year (1-unit increase)	3.0740	0.6276	4.8978	0.0000	0.8718	0.3812	2.2872	0.0234
Presence of fluid end LP: yes vs no	−4.7143	2.2393	–2.1052	0.0364	−5.0244	2.5849	−1.9438	0.0536
Bilateral diagnosis: yes vs no	2.7481	2.4866	1.1051	0.2703	3.3126	2.8576	1.1592	0.2480

*Adjusted R² for the model is 0.45, **Patients with complete data were 225 for year 1.

*Adjusted R² for the model is 0.43, **Patients with complete data were 178 for year 2.

IstCA, first-year completer analysis set; 2ndCA, second-year completer analysis set; ETDRS, early treatment diabetic retinopathy study; LP, loading phase; PCV, polypoidal choroidal vasculopathy; RAP, retinal angiomatous proliferation; SE, standard error; VA, visual acuity.